摘要
目的：比较重组链激酶（ｒ－ｓｋ）与重组组织型纤溶酶原激活剂（ｒｔ－ＰＡ）静脉溶栓对急性心肌梗塞的效果与其副作用；方法：急性心肌梗塞患者发病６ｈ内者２６例给予静脉ｒｔ－ＰＡ，另２７例给予静脉内ｒ－ｓｋ溶栓；结果：ｒｔ－ＰＡ组、ｒ－ｓｋ组临床血管再通率分别为８４．６％与７７．３％（Ｐ＞０．０５），前者局部出血并发症为１１．５％，呼吸道出血为７．７％，后者分别为３．７％与０（Ｐ＞０．０５）；结论：静脉ｒ－ｓｋ溶栓血管再通率及出血并发症与ｒｔ－ＰＡ无明显差异。
Objective:T5,5BZTocomparetheeffectivenessandcomplicationsofintravenousrecombinantstreptokinase(rsk)andrecombinanttissuetypeplasminogenactivator(rtPA)inpatientswithacutemyocardialinfarction(AMI). Methods: 26patientsinrtPAgroupand27patientsinrskgroupwereincludedinthestudy,andeitherofthemweresimultaneouslytreatedwithintravenousrskrtPA. Results: TheclinicalreperfusionratesinrtPAandrskgroupwere84.6%and77.3%(P>0.05),respectively.WhileinrtPAgroupthepartialbleedingcomplicationratewas11.5%.respiratorybleedingratewas7.7%.Inrskgroupwere3.7%and0(P>0.05),respectively. Conclusion:5BZThepatientswithAMItreatedwithintravenousrskrtPAwithin6hoursafteronsetofsymptomshadntobviousdifferenceofreperfusionratesandhemorrhagiccomplications.
出处
《河北医学》
CAS
1999年第7期4-6,共3页
Hebei Medicine
关键词
重组链激酶
RT-PA
静脉溶栓
急性
心肌梗塞
Recombinantstreptokinase
Recombinanttissuetypeplasminogenactivator
Intravenousthrombolytictherapy
Acutemyocardialinfarction
